The polycystic ovarian syndrome (PCOS) treatment market size is expected to grow from US$ 3.46 billion in 2023 to US$ 5.26 billion by 2031; it is anticipated to record a CAGR of 5.4% from 2023 to 2031.

Market Drivers of the Polycystic Ovarian Syndrome (PCOS) Treatment Market

Governments around the world are recognizing the growing prevalence of PCOS and the impact it has on women's health, fertility, and overall well-being, leading to increased funding and resources dedicated to research and treatment initiatives. Government support for research in the PCOS treatment market also plays a crucial role in driving advancements in personalized medicine and precision healthcare. By funding studies that investigate the genetic, hormonal, and metabolic factors underlying PCOS, governments are helping to identify targeted therapies that can address the specific needs of individual patients. For instance, the government of India, through the Indian Council of Medical Research (ICMR), has launched a large-scale representative country-wide epidemiological multicentric study on PCOS. Similarly, the United States passed a resolution that recognizes the importance of polycystic ovary syndrome (PCOS) and designated September 2021 as "PCOS Awareness Month."

Moreover, government initiatives are instrumental in promoting interdisciplinary collaboration among healthcare providers, researchers, policymakers, and patient advocacy groups. By fostering partnerships and knowledge-sharing across different sectors, governments can create a more holistic approach to managing PCOS that addresses the condition's physical symptoms and emotional and psychological aspects. Thus, the increasing government initiative and support for research in the field of reproductive health fuels the polycystic ovarian syndrome (PCOS) treatment market growth.

Opportunities in the Polycystic Ovarian Syndrome (PCOS) Treatment Market

Emerging countries such as India, China, Argentina, Brazil, UAE, and South Africa are expected to offer significant growth opportunities for polycystic ovarian syndrome (PCOS) treatment market players due to rising disposable incomes, expanding PCOS patient population, increasing R&D activities, improving healthcare infrastructure, growing disease awareness, and relatively lenient guidelines compared to developed countries. This is an indication of strength in the PCOS treatment market. As PCOS incidence rises in these countries, there is a greater demand for various PCOS treatment options. Furthermore, the governments of these countries are focusing on increasing access to effective and cutting-edge healthcare services for a larger proportion of their populations and improving reimbursement coverage. The expansion of healthcare products across these nations is driven by the quick increase in per-capita healthcare spending and the growing public demand for affordable healthcare services. For instance, According to the World Economic Forum, as of 2022, Russia, Brazil, China, India, and South Africa collectively accounted for a third of global health spending. As per the World Bank, health spending in India and China increased by 3.01% and 5.35%, respectively, from 2018 to 2019. Thus, the increasing healthcare expenditure in emerging countries will likely provide opportunities for the growth of the polycystic ovarian syndrome (PCOS) treatment market during the forecast period.

Polycystic Ovarian Syndrome (PCOS) Treatment Market: Segmental Overview

By product, the market is bifurcated into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held a larger market share in 2023. The clomiphene citrate segment is anticipated to register a higher CAGR during the forecast period. The market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023. It is further anticipated to register the highest CAGR during the forecast period.

Polycystic Ovarian Syndrome (PCOS) Treatment Market: Geographical Overview

The polycystic ovarian syndrome (PCOS) treatment market in Asia Pacific is expected to grow at the highest CAGR during the forecast period. North America accounted for the largest share of the global market in 2023. In 2023, North America held the largest market share. The growing adoption of the latest medical device technologies, the prevalence of PCOS, and product innovations by key players contribute to the expansion of North America's polycystic ovarian syndrome (PCOS) treatment market size. For instance, According to the US Department of Health & Human Services, in the United States, PCOS is a common cause of female infertility in the US, which affects ~6% to 12% (~5 million) of US women of reproductive age. Similarly, according to the study "Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis," published in July 2023 in the American Journal of Obstetrics and Gynecology, the incidence rate of PCOS in the US is 42.5 cases per 10,000 people every year. Furthermore, various organizations in the country offer comprehensive evaluation, create awareness, and focus on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively engaged in research to study the cause of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness favor the polycystic ovarian syndrome (PCOS) treatment market progress.

A few of the major primary and secondary sources referred to while preparing the report on the polycystic ovarian syndrome (PCOS) treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).